Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $12.7252W HIGH $14.68
Volume
50.99 K
Value Traded
1.32 M
Short % Float
2.13%
-12.94%Week
-30.98%1 Month
-65.96%3 Month
-75.29%6 Month
+6.67%5 Year
+6.67%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
93.36 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
90.41 M
Total Shares
28.21 M
Float Shares
8.09 M
Insiders
68.52%
Institutions
0.09%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CNXU Catalyst Timeline
Dated clinical, regulatory and corporate events for Conexeu Sciences Inc.
Past FDA Catalysts and PDUFA Decisions
How CNXU actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Conexeu Sciences Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every CNXU program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Bogart David RobertDirector, Officer (Chief Commercial Officer) | Option | 750,000 1,812,500 held | $0.00 | 09/25/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CNXU
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in CNXU for Q2 2026. | ||||
CNXU Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CNXU ranks across every disease it competes in
Competitive Position is a premium feature
See how CNXU ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCNXU News
CNXU▲ +5.4%today
Conexeu Sciences Advances Ten Minute Tissue™ Toward Planned FDA 510(k) Submission
Conexeu Sciences Inc. is making significant progress towards its planned FDA 510(k) submission for Ten Minute Tissue™, a wound care device, expected in early 2027. The company has successfully scaled up manufacturing processes and produced multiple batches of CXU™ material that meet regulatory specifications. This advancement is crucial for both regulatory testing and future market readiness.
Read more →CNXU▼ -18.2%on this news· ran to -31% by day 3
Conexeu Sciences Sets September and October 2026 Conference Schedule
Conexeu Sciences Inc. has announced its participation in several investor and industry conferences scheduled for September and October 2026. These events will allow the company's management to engage with analysts and stakeholders while advancing their investigational tissue-restoration platform. The company aims to target significant markets, including wound care and tissue restoration, with an anticipated regulatory submission in early 2027.
Read more →CNXUConexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration
Conexeu Sciences Inc. is pioneering a new category in medical aesthetics focused on regenerative tissue restoration. Their CXU™ platform aims to enhance soft tissue through biological restoration rather than merely replacing lost volume. The regenerative aesthetics market is expected to grow significantly, supported by increasing scientific interest in extracellular matrix technologies. Conexeu is preparing for a 510(k) submission in early 2027.
Read more →CNXUThe GLP-1 Boom Created a $2 Billion Opening in Aesthetics. One Preclinical Biotech Is Building the Product to Fill It.
Conexeu Sciences Inc. is leveraging its CXU™ platform to address a burgeoning market in injectable aesthetics, particularly for large-volume body restoration. Following a successful 12-month preclinical study, the company aims to fill a gap left by existing products. The market for GLP-1-related aesthetic care is expected to grow from $0.7 billion to $2 billion by 2030, indicating strong potential for Conexeu's innovations.
Read more →CNXU▼ -8.1%on this newsshared move
The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It
Conexeu Sciences is advancing its CXU™ platform, targeting the large-volume injectable aesthetics market, particularly in body contouring. The company has completed a 12-month preclinical study demonstrating the potential of CXU™ to restore significant body volume. With the aesthetics market projected to grow to $2 billion by 2030, Conexeu aims to fill a crucial gap in injectable solutions. The company plans to submit for regulatory approval in early 2027.
Read more →CNXUOne Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
Conexeu Sciences Inc. has completed the P.R.O.O.F phase of its CXU preclinical program, achieving key objectives in facial and body applications. This milestone supports the company's strategy to advance a single formulation in regenerative medicine. The next regulatory step is a predicate-based 510(k) submission targeted for Q1 2027, although the findings are still preclinical and unverified.
Read more →CNXU▼ -15%on this newsshared move
A $190 Billion Weight-Loss Boom Exposed a Tissue-Restoration Gap, and One Nasdaq Company Is Moving to Fill It
Conexeu Sciences Inc. has completed the P.R.O.O.F phase of its CXU preclinical program, targeting the medical aesthetics injectable market. This market is expanding due to the weight-loss drug boom, which has created a need for tissue restoration that current injectables cannot meet. The company aims to address this gap with its innovative platform, although it faces competition from established players. The first regulatory submission is anticipated in Q1 2027, but success is not guaranteed.
Read more →CNXU▼ -12.1%on this newsshared move
A $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today’s Injectables Were Not Built to Fill
Conexeu Sciences has completed its 12-month P.R.O.O.F preclinical study, demonstrating the efficacy of its CXU™ platform in tissue restoration. The study met essential benchmarks for both small and large-volume applications, positioning the company for entry into the medical aesthetics market. The anticipated growth in this sector, driven by weight-loss treatments, highlights a significant market opportunity for Conexeu.
Read more →CNXUConexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform
Conexeu Sciences has inaugurated a new research and development facility at adMare BioInnovations' M4 Innovation Centre in Vancouver. This facility aims to enhance the company's regenerative tissue technologies, including the CXU™ platform and B.R.E.A.S.T.™ matrix. The opening marks a significant milestone in Conexeu's growth and its commitment to advancing patient care in tissue regeneration.
Read more →CNXU▼ -13%on this news
Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing
Conexeu Sciences Inc. has expanded its board from six to nine directors and appointed a Chief Commercial Officer to enhance its leadership team. The new appointments bring significant experience in healthcare, finance, and strategic growth, aligning with the company's goals for commercialization and development of its regenerative tissue technologies. The company is poised for growth following its recent Nasdaq listing.
Read more →CNXUConexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU™ Wound Care Program
Conexeu Sciences has reported significant progress in scaling up manufacturing and preparing for a 510(k) submission for its CXU™ wound care device. The company has transitioned from research to manufacturing and testing phases, receiving FDA feedback that aids in development planning. The anticipated submission is targeted for the first quarter of 2027, contingent on successful testing and regulatory compliance.
Read more →CNXUConexeu Sciences to Ring Nasdaq Bell on June 10, 2026
Conexeu Sciences Inc. will ring the Nasdaq Closing Bell on June 10, 2026, to celebrate its recent public listing under the ticker CNXU. CEO Miles Harrison and the leadership team will participate in the ceremony, acknowledging the contributions of employees and investors. The company is focused on advancing its tissue regeneration technologies, including the innovative B.R.E.A.S.T. product.
Read more →CNXU▲ +6.9%on this news
UPDATE - Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine
Conexeu Sciences has initiated a preclinical development program for its B.R.E.A.S.T.™ bioregenerative matrix at the Wake Forest Institute for Regenerative Medicine. This program aims to evaluate the matrix's durability, integration, and resorbability, marking a significant step in advancing regenerative medicine. The technology is designed to offer a resorbable alternative to traditional breast implants.
Read more →CNXU▲ +10.2%on this newsshared move
Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It
Conexeu Sciences Inc. (NASDAQ:CNXU) began trading on May 21, 2026, as a preclinical-stage company focused on regenerative medicine. Their CXU™ platform aims to address significant unmet needs in wound care and breast reconstruction. The company plans to submit a 510(k) application in early 2027, leveraging its patented technology to support tissue regeneration. This listing marks a strategic move to secure capital for further development.
Read more →About Conexeu Sciences Inc.
Headquarters50 WEST LIBERTY STREET, SUITE 880, RENO, NV, 89501
Founded2022
BIOPHARMAWATCH ELITE PLUS
Trade the next CNXU catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime